cyrilzakka/clinical-trials huggingface dataset:
Effect of Supragingival Control Versus Supra- and Subgingival Control in the Periodontal Health During the Maintenance

Seventy patients will be previously treated for moderate-to-severe periodontitis according to their individual needs. Thirty days after completion of periodontal treatment, these patients will be randomized to one of the following groups of periodic preventive maintenance (PPM): G1 - performed only control supragingival; G2 - performed supra and subgingival control (when necessary).

The maintenance consultations will be scheduled every 3 months for 24 months. The hypothesis is that the effect of the supragingival control (conducted over 24 months) will be similar to the effect of the supra- and subgingival control combined, above the restoration and progression of periodontitis.

This randomized clinical trial, single-blind, aims to compare the effect of the supragingival biofilm control with the effect of supra- and subgingival biofilm control, performed by the patient-professional binomial, in periodontal patients treated, above the restoration and progression of periodontitis during the preventive periodic maintenance (PPM). Seventy patients with moderate-to-severe periodontitis, aged from 35 years, will be included. Participants will be periodontally treated according to their needs. After 30 days of the end of treatment, participants will be randomized (stratified for smoking) in two groups: Group 1 (G1)- Supragingival biofilm control; Group 2 (G2)- Supra and subgingival biofilm control. MPP consultation will take place every 3 months, for 24 months, in which the G1 will only receive procedures of supragingival biofilm control, and G2 will receive, beyond the supragingival control, subgingival interventions.

Eligibility Criteria:
Inclusion Criteria:

* age from 35 years;
* present at least 12 teeth in the mouth;
* patients diagnosed with moderate-to-severe periodontitis according to the criteria of the AAP (1999):

  * to present ≥ 2 interproximal sites with AL ≥ 6 mm AND ≥1 interproximal site with PD ≥ 5 mm; or
  * to present ≥ 2 interproximal sites with AL ≥ 3mm OR ≥ 2 interproximal sites with PD ≥ 5 mm (in different teeth).

Exclusion Criteria:

* presence of systemic conditions unfavorable to periodontal treatment (diabetes, cardiovascular changes with antimicrobial prophylaxis indicated);
* positive history of periodontal treatment and maintenance in the 12 months preceding the study;
* positive history of using anti-inflammatory drugs and antibiotics in the 3 months prior to initial consultation;
* patients in use of fixed orthodontic appliance;
* pregnant patients.
Longitudinal Monitoring of Inflammation in Cirrhosis

Longitudinal monitoring of inflammation using skin devices may help predict outcomes compared to traditional blood draws


Eligibility Criteria:
Healthy Volunteers

Inclusion Criteria:

1. Age \>18 years
2. Able to give consent

Exclusion Criteria:

1. Unable/unwilling to consent
2. Chronic diseases
3. Unable to come in daily or be available daily for 3 days.

Outpatients with Cirrhosis:

Inclusion criteria:

1. Age \>18 years
2. Able to give consent
3. Cirrhosis defined by any one of the following

   1. Cirrhosis on liver biopsy or transient wave elastography
   2. Nodular liver on imaging
   3. Endoscopic or radiological evidence of varices in a patient with chronic liver disease
   4. Platelet count \<150,000/mm3 and AST/ALT ratio \>1 in a patient with chronic liver disease
   5. Patients with frank decompensation (ascites, HE, variceal bleeding, hepato-pulmonary syndrome)

Exclusion criteria:

1. Unable/unwilling to consent
2. Unclear diagnosis of cirrhosis
3. Unable to come in daily or be available daily for 3 days.
4. Inflammatory bowel disease or other diseases that require immunosuppressive therapy use

Inpatients with Cirrhosis:

Inclusion criteria:

1. Age \>18 years
2. Able to give consent
3. Cirrhosis defined by any one of the following

   1. Cirrhosis on liver biopsy or transient wave elastography
   2. Nodular liver on imaging
   3. Endoscopic or radiological evidence of varices in a patient with chronic liver disease
   4. Platelet count \<150,000/mm3 and AST/ALT ratio \>1 in a patient with chronic liver disease
   5. Patients with frank decompensation (ascites, HE, variceal bleeding, hepato-pulmonary syndrome)

Exclusion criteria:

1. Unable/unwilling to consent
2. Unclear diagnosis of cirrhosis
3. Unable to be seen daily or able to come in daily for 3 days (if discharged in between)
4. Inflammatory bowel disease or other diseases that require immunosuppressive therapy use
MRI in Ovarian Tumors

Role of multi paramrtric MRI and MRI perfusion in indetermint ovarian lesions by using ORADS MRI

Aim of study the purpose of this study is to investigate the capabilities of multi parametric MRI including DCE perfusion and DWI to discriminate between benign and malignant ovarian masses .

Eligibility Criteria:
Inclusion Criteria: females with ovarian masses

-

Exclusion Criteria:

* females with known benign ovarian masses
Nicotine Replacement Therapy (NRT) Sampling and Selection to Increase Medication Adherence

To determine the preliminary impact on Nicotine Replacement Therapy (NRT)adherence and examine the underlying mechanisms of action associated with adherence.

Adherence is a critical target for successful smoking cessation, with good adherence associated with a three-fold increase in cessation rates relative to poor adherence. Psychoeducational interventions focused on increasing adherence to NRT do not result in behavioral change (e.g., smoking cessation). Experiential approaches, such NRT sampling with practice quit attempts (PQAs), are based on learning theory models of behavioral change and have resulted in increased motivation, self-efficacy, adherence, and abstinence relative to psychoeducation or motivational interventions. However, nicotine sampling still relies of the participant using NRT outside of session, which may not occur. Providing an experiential intervention in which the NRT is sampled and any problems with NRT reframed during the session may provide a powerful learning experience that can increase in home sampling with PQAs and long-term adherence, ultimately increasing the likelihood of smoking cessation. This may be particularly relevant for low-income smokers who hold more negative views of NRT, have lower health literacy, and are less likely to use medication during cessation attempts.

Eligibility Criteria:
Inclusion Criteria:

a) 18 years or older; b) qualifying as low income (as defined by making \<150% above the poverty line or \<$22,260 as a single or \<$45,570 for a family of four); c) Smoking at least 5 cigarettes per day (CPD) for the past year and a carbon monoxide (CO) level of less than 8 ppm to ensure daily smoking. This relatively low cutoff was chosen due to the expectation of enrolling a large \>50% African-American who average \<10 CPD compared to Whites who average \~15 CPD.; and d) English speaking.

Exclusion Criteria:

a) Living in a restricted environment (e.g., prison or jail facility, etc.); b) Pregnant or nursing (all women will be required to use an acceptable form of contraception); c) Currently enrolled in a smoking cessation treatment program, using NRT products, or prescribed bupropion or varenicline; d) Known allergy to any of the nicotine replacement products or sensitivity to adhesive used in nicotine patches; e) Trouble breathing, a pulmonary condition, or sinus problems; f) Within one month post-myocardial infarction or untreated severe angina; g) poor dentation or temporomandibular joint (TMJ) problems such as unable to use nicotine gum; h) Cognitive impairment or unstable psychiatric condition that interferes with the informed consent process (individuals stable on psychiatric medications will be included); or i) Daily or exclusive use of other tobacco products (e.g., electronic cigarettes, little cigars, etc.).
The Effect of Motivational Interviews Based on the Transtheoretic Model on Pregnant Women's Smoking Cessation Behaviors

This study is planned to determine the effect of online motivational interviews based on the transtheoretic model on the prediction of smoking cessation success, self-efficacy levels and smoking cessation behavior of pregnant women.It is an experimental research.

The population of the research will be the pregnant women registered in the family health center in Sivas city center.The sample of the study will consist of pregnant women who smoke and agree to participate in the study.Power analysis was calculated using G \* Power 3.1.9.2 program. With 76% effect size, 90% power and 0.05 significance level, the required sample size was determined as 30 individuals per group, and 60 individuals in total. It was decided to include 66 individuals, 33 individuals in the intervention group and 33 individuals in the control group, by taking 10% more of the calculated sample against the possibility of sample loss during the study.Smoking Cessation Success Prediction Scale Self-Efficacy Level Scale Decision-Making Balance Scale Behavior Change Stage Diagnostic Questionnaire Fagerström Nicotine Addiction Test will be used as measurement tools.Pregnant women who agree to participate in the study will fill in the Informed Consent Form and other measurement tools.Interviews with the pregnant women in the intervention group will be held face-to-face via the Zoom application for a total of 6 times.Data collection forms will be applied to the control group at the first interview and at the last interview (6 months later), and for the intervention group at the first interview, 3 months and 6 months later, a total of 3 times.After each assessment moment, the data obtained will be exported to the "Statistical Package for Social Sciences Software" (SPSS).

Eligibility Criteria:
Inclusion Criteria:

* Volunteering to participate in the research
* Not completing the 16th week of pregnancy
* Being 18 years or older
* To smoke at least 1 cigarette a day
* Being able to use a smart phone or computer and having internet
* Being literate

Exclusion Criteria:

* Unable to use a computer or smartphone
* Being at the 17th and above gestational week
* Having any mental illness
* Illiterate pregnant women
Study of the IgA Repertoire During IgA Deposition Nephropathy.

IgA plays a major role in mucosal and systemic immunity but retains mysterious and ambivalent aspects. They can thus, depending on the situation, prove to be capable of triggering either a protective inflammatory response or, on the contrary, anti-inflammatory and inducing tolerance. Similarly, and for reasons that remain very poorly understood, they can be involved in pathologies where the immune system is itself an aggressor of the body and responsible for immunopathological lesions.

The investigator formulates the hypothesis that an inappropriate response of the mucosal immune system to one or more antigens leads to a synthesis of IgA of bad affinity favoring a deposit at the level of the mesangium. It seems important to verify this point by analyzing the IgA repertory of patients with N-IgA and comparing it to that of a control population.

IgA plays a major role in mucosal and systemic immunity but retains mysterious and ambivalent aspects. They can thus, depending on the situation, prove to be capable of triggering either a protective inflammatory response or, on the contrary, anti-inflammatory and inducing tolerance. Similarly, and for reasons that remain very poorly understood, they can be involved in pathologies where the immune system is itself an aggressor of the body and responsible for immunopathological lesions.

the investigator formulates the hypothesis that an inappropriate response of the mucosal immune system to one or more antigens leads to a synthesis of IgA of bad affinity favoring a deposit at the level of the mesangium. It seems important to verify this point by analyzing the IgA repertory of patients with N-IgA and comparing it to that of a control population.

Eligibility Criteria:
Inclusion Criteria:

* Control population:

  * person between the ages of 18 and 55 (persons matched to age and sex (75% male) (N-IgA is more common in humans) free from any pathology.

oAbsence of proteinuria and hematuria on urine sample (search by strip).

* Patients with N-IgA

  * 40 patients with N-IgA whose diagnosis was confirmed by renal biopsy. These may be previously known patients who have not received treatment with corticosteroids or immunosuppressants for 12 months or new patients. The incidence of N-IgA is 20 patients per Mh; the number of incident patients with N-IgA is 10-15 per year in the nephrology department. The recruitment of 40 patients over 1 year is feasible.
  * Participant's written consent

Exclusion Criteria:

* Secondary or associated N-IgA (infection, malignant disease, inflammatory bowel disease,
* Rheumatic autoimmune disease or other;
* treatment with corticosteroids or immunosuppressants for less than 12 months.
* person on dialysis
Pegylated Interferon Lambda Treatment for COVID-19

Prospective randomized trial to assess the antiviral efficacy of Pegylated Interferon Lambda (180 mcg SC injection) vs.placebo in up to 20 subjects with COVID-19 infection.

The study objective is to assess the efficacy of Pegylated Interferon Lambda (180 mcg) vs. placebo in inducting quantitative PCR negativity at day 7

Eligibility Criteria:
Inclusion Criteria:

* Able to provide informed consent
* Confirmed COVID-19 diagnosis based on PCR analysis of respiratory secretions
* Positive SARS-CoV-2 RT-PCR test must be within 48 hours of randomization

Exclusion Criteria:

* Clinically-significant illness or any other major medical disorder that in the opinion of the investigator, may interfere with subject treatment, assessment or compliance with the protocol
* Treatment with IFN or other immunomodulatory/immunosuppressive agent within 12 months before screening.
* Respiratory compromise requiring ventilatory support other than nasal cannula (mask, bipap or intubation and mechanical ventilation)
* History of treatment with any of the following medications within five half-lives or 30 days before administration of the study drug (whichever is longer): anti-IL-6, anti-IL6R antagonists, Janus kinase inhibitors, ustekinumab (anti-IL-12/23), or anti IL-23 agents (guselkumab).
* Life threatening SAE during the screening period
* Pregnant or Nursing Females
* Platelet count \<90,000 cells/mm3
* WBC count \<3,000 cells/mm3
* ANC \<1,500 cells/mm3
* Hb \<11 g/dL for women and \<12 g/dL for men
* CrCl \< 50 mL/min
* Bilirubin level ≥ 1.5x ULN
* INR ≥1.5 (except in the setting of concomitant anticoagulant use)
* CRP \> 200 mg/L
* Clinically-relevant alcohol or drug abuse within 12 months of screening
* Known hypersensitivity to Interferons
* Current or planned participation in an investigational new drug (IND) trial from 30-days prior to randomization through Day 14 post treatment
Marginal Bone Loss in Single Implant Restaurations With Different Methods

The investigator is going to measure the marginal bone loss in single implant restaurations with three different methods: direct overcast, milled cad/cam direct to implant restauration and milled cad/cam implant restauration using an transepithelial pilar

The investigator has chosen a statistically significant sample (compared with other similar studies) to analize the bone marginal loss in different types of restauration with single dental implants

Eligibility Criteria:
Inclusion Criteria:

* patients with single implants restaurations treated in Leon University

Exclusion Criteria:

* pregnant
* mayor heath issues
* patients who do not agree to participate
Impact of EsTOCma on OCD Family Members

The goal of this clinical trial is to test the acceptability, feasibility, and effectiveness of esTOCma in families and relatives of individuals with obsessive-compulsive disorder (OCD).

Specifically, a randomized controlled trial with two conditions (experimental and control) has been carried out in a sample of families and relatives of individuals with obsessive-compulsive disorder to assess pre-post-intervention changes. Researchers will compare experimental and control group to see if after using the app there is: lower stigma, higher knowledge and understanding about OCD, higher intention to seek help, and higher self-esteem and lower obsessive-compulsive symptoms. and there are no changes in the control group.

The experimental group received the intervention through the esTOCma app.


Eligibility Criteria:
Inclusion Criteria:

* having signed the informed consent
* being over 18 years of age;
* having an Android or iOS mobile device with Internet access
* being a family member of a person diagnosed with OCD.

Exclusion Criteria:

* not completing one or more of the evaluation time points (pre- or post-intervention)
* not finishing the intervention (experimental group only)
Effect of Combined Red and Near Infrared Light-emitting Diode (LED) Therapy on Tissue Regeneration Post Laser Treatment

The purpose of this study is to evaluate the effect of light therapy on wound healing after laser treatment.

This study sets out to evaluate the effect of a combination of near infrared (830 nm) red (633 nm) and blue (465nm) light-emitting diode (LED) therapy on wound healing after laser application.

Eligibility Criteria:
Inclusion Criteria:

Adults aged 18 years or older with no active cutaneous disease on bilateral ventral biceps, close to the axilla.

Subjects shall have given written informed consent for both the LED therapy and for clinical photography.

Exclusion Criteria:

Patients will be excluded if any of the exclusion criteria applies

* Subjects refuse to give informed consent for either the phototherapy or the clinical photography.
* Subjects have previous photosensitivity problems (solar urticaria, etc.).
* Subjects are taking any systemic drug or applying any topical drug with known photosensitizing properties.
* Subjects taking any systemic drug with known immunosuppressant properties.
* Subjects applying any medications to the research site (inner biceps, close to the axilla).
* Subjects have medical or psychosocial conditions associated with a risk of poor protocol compliance.
* Subjects are smokers or have smoked within the last 30 days prior to the trial.
* Subjects have epilepsy or a history of seizures
* Subjects currently taking cortisone injections or any other kind of steroid injections(s)
* Subjects with known cancer tumor in the treatment area or metastasis
The Effect of Propofol on Dexamethasone-induced Perineal Pruritus

patients may appear serious perineal itching, after injection of dexamethasone sodium phosphate injection its incidence is about 25% \~ 100%, and the incidence of the discomfort in females was much higher than that of the maleTo investigate the effect of propofol pretreatment on perineal pruritus induced by dexamethasone sodium phosphate injection and explore the possible machanisms.

40 patients scheduled for selective surgery,aged 18-65years,ASA physical status I\~II,BMI 18\~30kg/m2 were selected in this study.The patients were equally randomized into two groups: propofol (P) group and normal saline (N) group, 20 cases in each group. Before anesthesia induction, M group received intravenous injection of 0.3mg/kg propofol , while N group received corresponding intravenous normal saline of the same volume. After 1 min, both groups received intravenous injection of dexamethasone sodium phosphate injection of 10mg. The anesthesiologist assessed perineal irritation in both groups and recorded Ramsay scores,the number of cases, visual analogue scale(VAS) scores ,duration of itching and observed the occurrence of adverse reactions such as dizziness, hypotension and respiratory depression in the two groups.

Eligibility Criteria:
Inclusion Criteria:

* Elective female surgery patients, ages 18 to 65 years old, ASA Ⅰ or Ⅱ level, body mass index (BMI) of 18 \~ 30 kg/m2.

Exclusion Criteria:

* diabetes mellitus, paresthesia, allergy to narcotic drugs, routine preoperative use of narcotic analgesics, long-term use of hormones, drug and alcohol abuse, communication disorders in psychiatric disorders, pregnancy or lactation, and patients with severe systemic diseases and unwilling to undergo the trial.
Long-Term Impact of COVID-19 Restrictions on Physical Activity and Social Interactions in Young Adults

There are studies on the impact of quarantine measures taken during the COVID-19 pandemic on individuals' social interactions and physical activities. We think that the adaptation of individuals who have had COVID-19 infection to return to social and physical activities after restrictions may affect participation in these activities. The aim of this study is to investigate the long-term impact of COVID-19 restrictions on physical activity and social interaction in young adults, depending on whether they have had a COVID-19 infection.

Corona Virus Disease-19 was declared as a pandemic on 11 March 2020 by the World Health Organization. The fact that the measures taken to prevent the spread of the pandemic bring about a global quarantine process affects people's social interactions and physical activity levels with each other. The aim of this study is to investigate the long-term impact of COVID-19 restrictions on physical activity and social interaction in young adults, depending on whether they have had a COVID-19 infection. Physical activity levels were assessed with the short form of the International Physical Activity Questionnaire-Short Form. Social interactions and social phobias are Social Interaction Anxiety Scale and Social Phobia Scale were evaluated.

Eligibility Criteria:
Inclusion Criteria:

* Young adults aged 18-25
* Agreeing to participate in the study

Exclusion Criteria:

* Having mental retardation